Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
NCT ID: NCT03447964
Last Updated: 2018-10-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
128 participants
OBSERVATIONAL
2017-04-04
2017-09-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Characterization of Fatty Acid Composition of Triglycerides in Patients With Hypertriglyceridemia-induced Acute Pancreatitis
NCT04097990
Impact of Chlordecone on Active Chronic Hepatitis
NCT03373396
Cholic Acid for Hepatic Steatosis in Lipodystrophy
NCT00457639
Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus
NCT02871882
Effect of Plasma Ceramides on Peripheral Vascular Function
NCT05107869
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sphingoliplids are involved in development of various chronic metabolic diseases. Some ceramides species are implicated in pancreatic β-cell apoptosis and in insulin resistance in muscle, fat and liver. Some studies have shown association between inhibition of ceramide synthesis, insulin sensibility and lower hepatic steatosis. The deposition of hepatic lipids, especially triacylglycerol, defines the development of hepatic steatosis. However, sphingolipids appear to play an important role in non-alcoholic fatty liver disease (NAFLD) and in its progression. Changes in plasma shingolipids concentrations may also contribute to the pathogenesis in cardiovascular disease and atherosclerosis. Distribution of plasma sphingolipids concentrations in type 1 and type 2 diabetes has poorly been studied.
The objective of the CERADIAB study is to compare plasma sphingoliplids concentrations in type 1 and type 2 diabetic patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Type 1 diabetes
dosing of sphingolipids
dosing of sphingolipids
\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Type 2 diabetes
Dosing of sphingolipids
dosing of sphingolipids
\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dosing of sphingolipids
\- Measuring the concentration of many species of sphingomyelins, ceramides, dihydroceramides and sphingosine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* family dyslipidemia
* nonmetabolic hepatopathy
* severe renal failure
* corticosteroid or immunosuppressive therapy
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Groupe Hospitalier Pitie-Salpetriere
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joe Elie Salem
Assistant director, clinical investigation center Paris Est
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Groupe Hospitalier Pitié-Salpêtrière
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIC14-21-17-12
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.